Filing Details
- Accession Number:
- 0001179110-13-000444
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-01-04 15:49:11
- Reporting Period:
- 2013-01-02
- Filing Date:
- 2013-01-04
- Accepted Time:
- 2013-01-04 15:49:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 882095 | Gilead Sciences Inc | GILD | Biological Products, (No Disgnostic Substances) (2836) | 943047598 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1190578 | C John Martin | Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404 | Chairman And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2013-01-02 | 141,121 | $15.27 | 2,143,853 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2013-01-02 | 88,311 | $74.34 | 2,055,542 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2013-01-02 | 52,810 | $74.67 | 2,002,732 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Incentive Stock option (right to buy) | Disposition | 2013-01-02 | 141,121 | $0.00 | 141,121 | $15.27 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 1,552,331 | 2014-01-28 | No | 4 | M | Direct |
Footnotes
- Options vest over 5 years. 20% vest on the first anniversary of the date of grant. The balance vest 5% every three months over the remaining 4 years. The options expire 10 years from the grant date.
- The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- Sale prices reported for the transactions reported here range from $73.91 to $74.50. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- Sale prices reported for the transactions reported here range from $74.51 to $74.94. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
Billionaire Hedge Funds
